To treat active pharmaceutical ingredients, an industrial wastewater treatment provider has taken the initiative towards designing a friendlier approach.
FREMONT, CA: "Pharmaceutical companies worldwide have committed to reducing the environmental impact of their manufacturing operations," says Jonathan Rhone, President and CEO, Axine. "This project is a great example of how Axine is establishing a new standard of care for treating APIs in pharmaceutical manufacturing waste streams to help the pharmaceutical industry achieve its sustainability goals while reducing the cost, risk, and impact of pharmaceuticals in the environment." Axine Water Technologies, an on-site industrial wastewater treatment provider, has signed a multiyear service agreement with a leading pharmaceutical manufacturer. This agreement will treat wastewater which is contaminated with Active Pharmaceutical Ingredients (API) and solvents.
The agreement has provisions under which, Axine will design, build, and operate wastewater treatment facilities at the customers' site. The system will wipe out APIs from discharged water using Axine's proprietary electrochemical oxidation technology. Solutions that Axine provides, are enabling the pharmaceutical plant to generate savings immediately. The Axine solution enhances operational efficiency, eliminating over 100,000 miles of trucking and 8 million pounds of waste incineration. This, in turn, on the terms of the agreement can reduce greenhouse gas emissions.
Wastewater contains major pharmaceuticals that are challenging to eliminate from wastewater treatment plants. These particles are becoming ubiquitous in the ecosystem because they cannot be removed effectively by the traditional wastewater treatment plants due to their lethal and resistant performance. To validate the cost and performance of Axine's technology, the agreement follows successful treatability testing. This agreement will treat wastewater to meet local municipal wastewater permit requirements.
"Axine's innovative wastewater treatment technology is addressing a global problem in the pharmaceutical industry that will ensure safe treatment of wastewater amongst a wide range of sustainability, productivity and health benefits," says Leah Lawrence President and CEO, SDTC. "We're very pleased to support Axine's scale-up efforts to compete in international markets using cutting edge technologies to advance sustainability efforts around the world."
Axine has addressed the issue of eliminating pharmaceuticals in wastewater. It has integrated breakthrough technology with smart, modular system design and an innovative service model to solve the most robust wastewater pain cases. Axine has evolved from concept to scale-up and commercial deployment with multinational clients with a strategy to enable customers to generate savings, alleviate risk, reduce waste, simplify operations and greenhouse gas emissions, achieving sustainability goals. The company is backed by a global network of world-class research agencies, advisors, suppliers, partners, and investors in one of the world's top cleantech platforms. Axine's technology integrates proprietary electrodes, advanced catalysts, and reactors to achieve the most versatile and affordable solutions for treating high strength, harmful organics, and ammonia, eliminating waste. Axine's electrochemical solutions address a broad range of the finest organics up to 100,000 mg/L and ammonia up to 10,000 mg/L.